LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis

Efficacy and Safety of LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris

To compare the efficacy and safety of LEO 80185 gel with Dovobet® ointment in the treatment of psoriasis in Japanese subjects.

Study Overview

• Status: Completed
• Conditions: Psoriasis Vulgaris
• Intervention / Treatment: Drug: LEO 80185 gel; Drug: Dovobet ® ointment

Detailed Description

A phase 3, national, multi-centre, 4-week, prospective, randomised, controlled, parallel-group, open trial of LEO 80185 gel versus Dovobet® ointment in Japanese subjects with psoriasis vulgaris.

• Study Type: Interventional
• Enrollment (Actual): 213
• Phase: Phase 3

Contacts and Locations

Study Locations

• Japan
  • Hokkaido
    • Kitami-shi, Hokkaido, Japan, 090-0832
      • Medical Corporation Bikyukai Kokubu Dermatology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• 1. Informed consent has been obtained.
• 2. Japanese subjects
• 3. Aged 20 years or above
• 4. Clinical diagnosis of psoriasis vulgaris amenable to topical treatment of less than or equal to 30% BSA
• 5. A target psoriasis lesion on the scalp and on the non-scalp area of the body, each lesion of a minimum size of 10 cm2 and scoring at least 2 (mild) for each of the clinical signs (redness, thickness and scaliness).
• 6. Females of childbearing potential must have a negative result for a urine pregnancy test at Day 1 (Visit 1) and must agree to use an adequate method of birth control.
• 7. Able to communicate with the (sub)investigator and understand and comply with the requirements of the trial.

Exclusion Criteria:

• 1. Systemic use of biological treatments with a potential effect on psoriasis vulgaris
• 2. Systemic treatments with all therapies other than biological treatments with a potential effect on psoriasis vulgaris
• 3. PUVA therapy, UVB therapy or UVA therapy
• 4. Topical treatment of psoriasis on the areas to be treated with trial medication
• 5. Topical treatment of psoriasis on the face, genitals or skin folds with vitamin D analogues, potent or very potent corticosteroids or immunosuppressants
• 6. Topical treatment of conditions other than psoriasis with vitamin D analogues, potent or very potent corticosteroids or immunosuppressants
• 7. Planned initiation of, or changes in, concomitant medication that may affect psoriasis vulgaris
• 8. Patients with any of the following disorders (a) or symptoms (b) present on the areas to be treated with trial medication: (a) viral (e.g., herpes or varicella) lesions of the skin, fungal, spirochetal or bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, acne vulgaris, atrophic skin, striae atrophicae, ichthyosis, acne rosacea, ulcers, burns, frostbite, wounds, animal skin disease (scabies, crabs, lice, etc.) or (b) fragility of skin veins.
• 9. Other inflammatory skin diseases that may confound the evaluation of psoriasis vulgaris.
• 10. Erythrodermic, exfoliative or pustular psoriasis
• 11. Planned excessive exposure of areas to be treated with trial medication to either natural or artificial sunlight
• 12. Known or suspected disorders of calcium metabolism associated with hypercalcaemia, or albumin-corrected serum calcium above the reference range
• 13. Known or suspected severe renal insufficiency, severe hepatic disorders or severe heart disease.
• 14. Known or suspected hypersensitivity to any components of the investigational products.
• 15. Clinical signs or symptoms of Cushing's disease or Addison's disease
• 16. Treatment with any non-marketed drug substance
• 17. Current participation in any other interventional clinical trial
• 18. Previously randomised in this trial
• 19. Females who are pregnant, wishing to become pregnant or are breast-feeding

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LEO 80185 gel	Drug: LEO 80185 gel; calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
Active Comparator: Dovobet ® ointment	Drug: Dovobet ® ointment; calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Subjects With 'Overall Improvement' for the Target Lesion on the Scalp	'Overall improvement' for the target lesion on the scalp, defined as 'substantial resolution' of clinical signs and/or at least 'moderately improved' in the general change in the lesion. 'Substantial resolution' is defined as a clinical score for thickness and scaliness of 0 and a clinical score for redness of 1 or less in the severity of clinical signs of the lesion.	End of Week 4

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Subjects With 'Overall Improvement' for the Target Lesion on the Non-scalp Area of the Body	'Overall Improvement' for the target lesion on the non-scalp area of the body, defined as 'substantial resolution' of clinical signs and/or at least 'moderately improved' in the general change in the lesion. 'Substantial resolution' is defined as a clinical score for thickness and scaliness of 0 and a clinical score for redness of 1 or less in the severity of clinical signs of the lesion.	End of Week 4
The Change in the Sum of the Scores (Total Sign Score) for the Severity of the 3 Clinical Signs:Thickness, Scaliness, Redness From Baseline to End of Week 4 (Visit 1-4) for Each Target Lesion.	Severity was recorded for each of the 3 clinical signs according to the 9-point scales* below. *intermediate intervals (0.5, 1.5, 2.5, 3.5) serve as mid points between the defined grades. Redness 0=none (no erythema); slight (faint erythema, pink to very light red); mild (definite light red erythema); moderate (dark red erythema); severe (very dark red erythema) Thickness 0=none (no plaque elevation); slight (slight, barely perceptible elevation); mild (definite elevation but not thick); moderate (definite elevation, thick plaque with sharp edge); severe (very thick plaque with sharp edge) Scaliness 0=none (no scaling); slight (sparse, fine scale, lesions only partially covered); mild (coarser scales, most of lesions covered); moderate (entire lesion covered with coarse scales); severe (very thick coarse scales, possibly fissured) Negative change denotes a decrease in the score and therefore a decrease in disease severity.	From Baseline to end of Week 4 (Visit 1-4)

Collaborators and Investigators

• Sponsor: LEO Pharma
• Collaborators: CMIC Co, Ltd. Japan
• Investigators: Principal Investigator: Hidemi Nakagawa, MD, Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan

Study record dates

Study Major Dates

• Study Start: February 1, 2016
• Primary Completion (Actual): June 1, 2016
• Study Completion (Actual): June 1, 2016

Study Registration Dates

• First Submitted: January 26, 2016
• First Submitted That Met QC Criteria: January 26, 2016
• First Posted (Estimate): January 29, 2016

Study Record Updates

• Last Update Posted (Actual): July 27, 2021
• Last Update Submitted That Met QC Criteria: July 5, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Keywords: LEO 80185 gel, calcipotriol, betamethasone
• Additional Relevant MeSH Terms: Skin Diseases; Skin Diseases, Papulosquamous; Psoriasis
• Other Study ID Numbers: LP0076-1128